Mont-Saint-Guibert, Belgium, March 17, 2025: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. EsoBiotec is a leading in vivo cell therapy company with the mission to make these innovative treatments more accessible, effective and affordable. By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system...